Trial · NCT02606305
Adverse event totals33
The totals the trial posted for each group.
1 to 20 of 33
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | 0 | 3 |
| Total, all-cause mortality | Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | 5 | 126 |
| Total, all-cause mortality | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | 0 | 4 |
| Total, all-cause mortality | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | 0 | 4 |
| Total, all-cause mortality | Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | 0 | 10 |
| Total, all-cause mortality | Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | 0 | 4 |
| Total, all-cause mortality | Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | 0 | 5 |
| Total, all-cause mortality | Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | 0 | 7 |
| Total, all-cause mortality | Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | 0 | 4 |
| Total, all-cause mortality | Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | 4 | 56 |
| Total, all-cause mortality | Mirvetuximab Soravtansine + Bevacizumab + Carboplatin | 2 | 41 |
| Total, other adverse events | Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | 3 | 3 |
| Total, other adverse events | Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | 125 | 126 |
| Total, other adverse events | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | 4 | 4 |
| Total, other adverse events | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | 4 | 4 |
| Total, other adverse events | Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | 10 | 10 |
| Total, other adverse events | Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | 4 | 4 |
| Total, other adverse events | Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | 4 | 5 |
| Total, other adverse events | Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | 7 | 7 |
| Total, other adverse events | Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | 4 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02606305/event-totals